Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Equity Average: 2022-2025

Historic Equity Average for Entrada Therapeutics (TRDA) over the last 4 years, with Sep 2025 value amounting to $360.1 million.

  • Entrada Therapeutics' Equity Average fell 15.50% to $360.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $360.1 million, marking a year-over-year decrease of 15.50%. This contributed to the annual value of $335.5 million for FY2024, which is 47.51% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Equity Average stood at $360.1 million, which was down 9.61% from $398.4 million recorded in Q2 2025.
  • Entrada Therapeutics' Equity Average's 5-year high stood at $426.2 million during Q3 2024, with a 5-year trough of $218.3 million in Q2 2023.
  • Its 3-year average for Equity Average is $322.7 million, with a median of $349.6 million in 2024.
  • As far as peak fluctuations go, Entrada Therapeutics' Equity Average declined by 18.17% in 2023, and later soared by 87.92% in 2024.
  • Entrada Therapeutics' Equity Average (Quarterly) stood at $222.9 million in 2022, then increased by 9.70% to $244.5 million in 2023, then skyrocketed by 74.05% to $425.6 million in 2024, then declined by 15.50% to $360.1 million in 2025.
  • Its Equity Average stands at $360.1 million for Q3 2025, versus $398.4 million for Q2 2025 and $423.0 million for Q1 2025.